← All trials
NCT04343885
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 23, 2020
- Primary completion
- Apr 30, 2024
- Completion date
- Apr 30, 2024
- First posted
- Apr 13, 2020
- Last posted
- Apr 13, 2020
- Enrollment
- 140
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Peter MacCallum Cancer CentreLead sponsor
- Peter MacCallum Cancer CentreOverall official - principal investigator
- Department of DefenseCollaborator
- Advanced Accelerator ApplicationsCollaborator
- Australian and New Zealand Urogenital and Prostate Cancer Trials GroupCollaborator
- Australasian Radiopharmaceutical Trials networkCollaborator
- Australian Nuclear Science and Technology OrganisationCollaborator
- Peter MacCallum Cancer CentreCollaborator
- Movember FoundationCollaborator
- Prostate Cancer Research AllianceCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.